Efecto de la administración concomitante de indometacina o ibuprofeno en la farmacocinética de amikacina en neonatos prematuros

Cuesta Gruesvo, C; Gimeno Navarro, A; Marqués Miñana, M R; Peris Ribera, J E; Morcillo Sopena, F; Poveda Andrés, J L

doi:10.1016/S1130-6343(06)73965-4

Farmacia Hospitalaria

ISSN: 1130-6343

Farmacia Hospitalaria (Farm Hosp) is the official publication of the Spanish Society of Hospital Pharmacists (SEFH), a professional and scientific organization that currently has about 4.351 members.

The Mission of Farm Hosp is to be the support for health professionals for expanding the influence of projects, publications, and training programs, and to promote the exchange of experiences.

Vision Farm Hosp is:
- to increase the state of knowledge about the hospital pharmacy and whose actions should increase the adequate and safe use of medicines and health products.
- to be an instrument of exchange and dissemination of scientific knowledge of pharmacy practice through the best use and safe medication and health outcomes.

It is a peer-reviewed double-blind scientific journal aimed at publishing in the broad field of Hospital Pharmacy advances in Pharmacy Services. This journal included the following topics: Drug evaluation. Quality of life. Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) in the use of drugs. Monitoring medication. Pharmaceutical compounding. Medication administration. Management of Pharmacy Services (logistics, quality control). Technologies and information systems in the process of using medication. Medical devices. Patient Education. Pharmacist´s role in the society and /or in the Health System in Spain, and other topics related to clinical, scientific, and institutional role of hospital pharmacists.

Farmacia Hospitalaria publishes bimonthly (6 issues yearly) originals, short originals, reviews, clinical cases, special articles, protocols, consensus documents, clinical guidelines, letters to the editor, editorials.

All the articles are published in Spanish and English language regardless of the language in which they are received.

Farmacia Hospitalaria is an Open Access journal, whose content is available free of charge to users or their institutions. Users are authorised to read, download, copy, distribute, print, search, or link to entire texts of the articles in this journal without prior permission from the editor or author, according to the BOAI definition of Open Access. The papers may be re-used under the terms of the Creative Commons 4.0 license. (CC BY-NC-ND). Such use shall be subject to authorisation from SEFH, the journal owner.

Farmacia Hospitalaria journal charges no fees for submission of papers or publication of articles.

Adherence to international ethics recommendations

Manuscripts must follow the most recent recommendations of the International Committee of Medical Journal Editors (available at http://www.icmje.org).

The articles published in Farmacia Hospitalaria are indexed in PubMed and other 17 date bases:
- Evaluation databases: MEDLINE, DOAJ, Scopus, Latindex y Scimago Journal and Country Rank (SJR). Índice H: 18, quartile 3 (Medicine, miscellaneous / Pharmacology)
- Bibliographic databases: CINHAL, EMBASE Excerpta Medica, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), Índice Español de Ciencia Y Tecnología (ICyT), Índice Médico Español (IME), International Pharmaceutical Abstracts (IPA).
- Journal collections: Dialnet, Medes, Scientific Electronic Library Online (SciELO), REDIB, ScienceDirect, ClinicalKey.

Indexed in:

Web of Science, MEDLINE, Scopus, Scimago Journal and Country Rank (SJR), CINHAL, EMBASE, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), Índice Español de Ciencia Y Tecnología (ICyT), Índice Médico Español (IME), International Pharmaceutical Abstracts (IPA), DOAJ, Dialnet, Latindex, Medes, Scientific Electronic Library Online (SciELO), REDIB.

Objetivo: Evaluar si la administración concomitante de ibuprofeno o indometacina puede alterar los parámetros farmacocinéticos de amikacina y, por lo tanto, los niveles plasmáticos de la misma. Método: Estudio de cohortes retrospectivo mediante revisión de historias clínicas correspondientes a niños prematuros con ductus arterioso persistente tratados con amikacina e ibuprofeno, o bien amikacina e indometacina. Se ditribuyen en tres grupos: grupo 1: el tratamiento con amikacina fue previo a la administración de indometacina o ibuprofeno; grupo 2: tratados simultáneamente con amikacina e indometacina; grupo 3: tratados simultáneamente amikacina e ibuprofeno. Los parámetros farmacocinéticos, volumen de distribución y aclaramiento de amikacina se determinaron mediante el programa PKS (método de regresión no lineal). La semivida se determinó a partir de los parámetros anteriores. Resultados: Se incluyen 28 pacientes. No se hallan diferencias estadísticamente significativas entre los parámetros farmacocinéticos correspondientes a cada grupo del estudio. Conclusiones: Serían necesarios estudios con mayor número de pacientes y con las dosis recomendadas actualmente, en los que se evalúe la influencia de indometacina e ibuprofeno en la farmacocinética de amikacina en niños prematuros con ductus arterioso persistente.

Palabras clave:

Ductus arteriosus persistente

Niño prematuro

Ibuprofeno

Indometacina

Amikacina

Farmacocinética

Objective: To evaluate whether the concomitant administration of ibuprofen or indomethacin plus amikacin may alter the latter drug's pharmacokinetic parameters, and hence amikacin plasma levels. Method: Retrospective cohort study performed by reviewing the medical records of premature children with persistent ductus arteriosus receiving amikacin and ibuprofen, or amikacin and indomethacin. They were divided up into three groups: group 1: treatment with amikacin went before indomethacin or ibuprofen; group 2: simultaneously treated with amikacin and indomethacin; group 3: simultaneously treated with amikacin and ibuprofen. Pharmacokinetic parameters, distribution volume, and amikacin clearance were measured using the PKS program (a non-linear regression method). Half life was determined from previous parameters. Results: Twenty-eight patients were included. No statistically significant differences were found among pharmacokinetic parameters corresponding to each study group. Conclusions: Further studies are needed with a greater number of patients and currently recommended doses to assess the influence of indomethacin and ibuprofen in the pharmacokinetics of amikacin in premature children with persistent ductus arteriosus.

Keywords:

Persistent ductus arteriosus

Premature child

Ibuprofen

Indomethacin

Amikacin

Pharmacokinetics

Full text is only available in PDF

Tools

Indexed in:

Follow us:

Subscribe to our newsletter